Peer-Reviewed Publications

      Comprehensive systems biology analysis of a 7-month cigarette smoke inhalation study in C57BL/6 mice

      Ansari, S.; Baumer, K.; Boué, S.; Dijon, S.; Dulize, R.; Ekroos, K.; Elamin, A.; Foong, C.; Guedj, E.; Hoeng, J.; Ivanov, N. V.; Krishnan, S.; Leroy, P.; Martin, F.; Merg, C.; Peck, M. J.; Peitsch, M. C.; Phillips, B.; Schlage, W. K.; Schneider, T.; Talikka, M.; Titz, B.; Vanscheeuwijck, P.; Veljkovic, E.; Vihervaara, T.; Vuillaume, G.; Woon, C. Q.

      Published
      Jan 5, 2016
      DOI
      10.1038/sdata.2015.77
      PMID
      26731301
      Link to publication
      Topic
      Summary

      Smoking of combustible cigarettes has a major impact on human health. Using a systems toxicology approach in a model of chronic obstructive pulmonary disease (C57BL/6 mice), we assessed the health consequences in mice of an aerosol derived from a prototype modified risk tobacco product (pMRTP) as compared to conventional cigarettes. We investigated physiological and histological endpoints in parallel with transcriptomics, lipidomics, and proteomics profiles in mice exposed to a reference cigarette (3R4F) smoke or a pMRTP aerosol for up to 7 months. We also included a cessation group and a switching-to-pMRTP group (after 2 months of 3R4F exposure) in addition to the control (fresh air-exposed) group, to understand the potential risk reduction of switching to pMRTP compared with continuous 3R4F exposure and cessation. The present manuscript describes the study design, setup, and implementation, as well as the generation, processing, and quality control analysis of the toxicology and 'omics' datasets that are accessible in public repositories for further analyses.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.